viernes, 20 de noviembre de 2026

GLP-1 Receptor Agonists in MASH (Fatty Liver Disease): Emerging Therapeutic Potential (+++)...

https://www.news-medical.net/health/GLP-1-Receptor-Agonists-in-MASH-(Fatty-Liver-Disease)-Emerging-Therapeutic-Potential.aspx Can treatments targeting appetite and glucose regulation also change the course of fatty liver disease? Clinical trials examine how these drugs alter liver inflammation and scarring. Metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), is the inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD), linked to obesity, insulin resistance, and metabolic dysfunction. Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated therapeutic benefits through their effects on body weight, glucose regulation, and liver histology.1,2,3 MASH is characterized by excessive hepatic fat accumulation, inflammation, and hepatocellular ballooning, a form of liver cell swelling and injury, with or without fibrosis. It develops through interacting metabolic and inflammatory processes, including insulin resistance, lipid accumulation, and cellular injury. As fibrosis advances, the risk of serious liver-related complications increases.1,2,3 What Does Inflammation Do to the Body? https://www.news-medical.net/health/What-Does-Inflammation-Do-to-the-Body.aspx What is Fatty Liver? https://www.news-medical.net/health/What-is-Fatty-Liver.aspx

No hay comentarios:

Publicar un comentario